1. Home
  2. ROMA vs RNTX Comparison

ROMA vs RNTX Comparison

Compare ROMA & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ROMA
  • RNTX
  • Stock Information
  • Founded
  • ROMA 2018
  • RNTX 2001
  • Country
  • ROMA Hong Kong
  • RNTX United States
  • Employees
  • ROMA N/A
  • RNTX N/A
  • Industry
  • ROMA Savings Institutions
  • RNTX Biotechnology: Pharmaceutical Preparations
  • Sector
  • ROMA Finance
  • RNTX Health Care
  • Exchange
  • ROMA Nasdaq
  • RNTX Nasdaq
  • Market Cap
  • ROMA 46.7M
  • RNTX 40.3M
  • IPO Year
  • ROMA 2024
  • RNTX N/A
  • Fundamental
  • Price
  • ROMA $3.06
  • RNTX $1.47
  • Analyst Decision
  • ROMA
  • RNTX
  • Analyst Count
  • ROMA 0
  • RNTX 0
  • Target Price
  • ROMA N/A
  • RNTX N/A
  • AVG Volume (30 Days)
  • ROMA 243.6K
  • RNTX 30.1K
  • Earning Date
  • ROMA 08-01-2025
  • RNTX 08-13-2025
  • Dividend Yield
  • ROMA N/A
  • RNTX N/A
  • EPS Growth
  • ROMA N/A
  • RNTX N/A
  • EPS
  • ROMA N/A
  • RNTX N/A
  • Revenue
  • ROMA $1,029,120.00
  • RNTX N/A
  • Revenue This Year
  • ROMA N/A
  • RNTX N/A
  • Revenue Next Year
  • ROMA N/A
  • RNTX N/A
  • P/E Ratio
  • ROMA N/A
  • RNTX N/A
  • Revenue Growth
  • ROMA N/A
  • RNTX N/A
  • 52 Week Low
  • ROMA $0.46
  • RNTX $1.35
  • 52 Week High
  • ROMA $4.14
  • RNTX $4.40
  • Technical
  • Relative Strength Index (RSI)
  • ROMA 63.53
  • RNTX N/A
  • Support Level
  • ROMA $2.61
  • RNTX N/A
  • Resistance Level
  • ROMA $3.12
  • RNTX N/A
  • Average True Range (ATR)
  • ROMA 0.41
  • RNTX 0.00
  • MACD
  • ROMA -0.04
  • RNTX 0.00
  • Stochastic Oscillator
  • ROMA 51.71
  • RNTX 0.00

About ROMA Roma Green Finance Limited

Roma Green Finance Ltd is principally engaged in the provision of ESG, corporate governance and risk management as well as sustainability and climate change-related advisory services. The company works closely with its clients to help them understand, identify, manage and overcome various business matters arising from such factors related to ESG, sustainability and climate change. it provides tailored-made sustainability solutions to meet the client's specific needs. Its mission is to provide its clients with a one-stop destination for high-quality and holistic sustainability and climate change-related consulting services to support a more sustainable, balanced and inclusive future for its clients' organizations and the world.

About RNTX Rein Therapeutics Inc. Common Stock

Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.

Share on Social Networks: